Present Molecular Limitations of ON-Bipolar Cell Targeted Gene Therapy

van Wyk, Michiel; Hulliger, Elmar; Girod, Lara; Ebneter, Andreas; Kleinlogel, Sonja (2017). Present Molecular Limitations of ON-Bipolar Cell Targeted Gene Therapy. Frontiers in neuroscience, 11(161) Frontiers Research Foundation 10.3389/fnins.2017.00161

[img]
Preview
Text
fnins-11-00161.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (7MB) | Preview

Recent studies have demonstrated the safety and efficacy of ocular gene therapy based on adeno-associated viral vectors (AAVs). Accordingly, a surge in promising new gene therapies is entering clinical trials, including the first optogenetic therapy for vision restoration. To date, optogenetic therapies for vision restoration target either the retinal ganglion cells (GCs) or presynaptic ON-bipolar cells (OBCs). Initiating light responses at the level of the OBCs has significant advantages over optogenetic activation of GCs. For example, important neural circuitries in the inner retina, which shape the receptive fields of GCs, remain intact when activating the OBCs. Current drawbacks of AAV-mediated gene therapies targeting OBCs include (1) a low transduction efficiency, (2) off-target expression in unwanted cell populations, and (3) a poor performance in human tissue compared to the murine retina. Here, we examined side-by-side the performance of three state-of-the art AAV capsid variants, AAV7m8, AAVBP2, and AAV7m8(Y444F) in combination with the 4xGRM6-SV40 promoter construct in the healthy and degenerated mouse retina and in human post-mortem retinal explants. We find that (1) the 4xGRM6-SV40 promoter is not OBC specific, (2) that all AAV variants possess broad cellular transduction patterns, with differences between the transduction patterns of capsid variants AAVBP2 and AAV7m8 and, most importantly, (3) that all vectors target OBCs in healthy tissue but not in the degenerated rd1 mouse model, potentially limiting the possibilities for an OBC-targeted optogenetic therapy for vision restoration in the blind.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Physiology
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

van Wyk, Michiel; Hulliger, Elmar; Girod, Lara; Ebneter, Andreas and Kleinlogel, Sonja

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1662-4548

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Andreas Ebneter

Date Deposited:

08 Aug 2017 11:06

Last Modified:

24 Oct 2017 10:29

Publisher DOI:

10.3389/fnins.2017.00161

BORIS DOI:

10.7892/boris.98430

URI:

https://boris.unibe.ch/id/eprint/98430

Actions (login required)

Edit item Edit item
Provide Feedback